Gain Therapeutics, Inc. (GANX) Revenue History
Annual and quarterly revenue from 2018 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
GANX Revenue Growth
GANX Revenue Analysis (2018–2024)
As of May 8, 2026, Gain Therapeutics, Inc. (GANX) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q3 2025) recorded $0 in revenue.
Looking at the longer-term picture, GANX's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $133,928 in 2021.
When compared to Healthcare sector peers including ACMR (+15.2% YoY), RARE (+13.3% YoY), and FOLD (+20.0% YoY). Compare GANX vs ACMR →
GANX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| GANXCurrent | $0 | - | - | - | |
 ACMR | $901M | +15.2% | +41.9% | 12.1% | |
 RARE | $673M | +13.3% | +19.9% | -79.5% | |
 FOLD | $634M | +20.0% | +19.4% | 5.4% | |
 LGND | $167M | +64.8% | +6.8% | -13.5% |
GANX Historical Revenue Data (2018–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $0 | -100.0% | $0 | - | $-20,350,592 | - |
| 2023 | $55K | -58.4% | $55K | 100.0% | $-22,253,133 | -40328.3% |
| 2022 | $133K | -1.0% | $-8,110,440 | -6114.6% | $-17,777,045 | -13402.5% |
| 2021 | $134K | +363.7% | $-7,030,301 | -5249.3% | $-13,826,173 | -10323.6% |
| 2020 | $29K | -30.1% | $29K | 100.0% | $-3,479,449 | -12047.5% |
| 2019 | $41K | +100.4% | $41K | 100.0% | $-2,100,109 | -5084.9% |
| 2018 | $21K | - | $0 | - | $-1,028,318 | -4989.7% |
See GANX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs GANX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare GANX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonGANX — Frequently Asked Questions
Quick answers to the most common questions about buying GANX stock.
Is GANX's revenue growth accelerating or slowing?
GANX TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is GANX's long-term revenue growth rate?
Gain Therapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is GANX's revenue distributed by segment?
GANX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2018-2024 are available for download. Segment mix reveals concentration and diversification trends.